In today’s evolving biotech landscape, companies are under increasing pressure to remain strategically flexible as they navigate paths to liquidity and growth. Whether pursuing a public listing or positioning for acquisition, preparation is critical to maximizing value and avoiding costly missteps. This fireside chat brings together industry veterans and thought leaders to unpack what “readiness” truly means across both IPO and M&A pathways—and how biotech leaders can proactively prepare for either (or both) outcomes.
The session will explore two distinct topics:
- IPO readiness, outlining how biotech companies should effectively plan for the transition to public markets—from timing and operational preparedness to investor positioning
- M&A readiness, examining how companies can acclimate quickly to the rapidly evolving dynamics of the deal lifecycle and realize value while controlling risk.
The session will conclude with audience Q&A, offering attendees the opportunity to gain practical insights tailored to their own strategic priorities.